AbbVie strengthened its manufacturing capabilities by breaking ground Thursday on a new US$223 million expansion of its Singapore manufacturing facility. This new investment will add more than 100 jobs and new biologics manufacturing capacity to AbbVie’s global network. Located in…
With an investment of EUR 120 million, the company will increase the manufacturing capacity of new and existing medications, some of them in the late-stage development of the company’s strong innovation pipeline. The main disease areas include cardio-renal-metabolic (CRM) diseases,…
Novo Nordisk announced the investment of more than 16 billion Danish kroner (2.1 billion euros) starting in 2023 to expand the existing production site in Chartres, France, for the current and future product portfolio within serious chronic diseases. The investment…
Novo Nordisk announced plans to invest more than 42 billion Danish kroner starting in 20231 to expand existing manufacturing facilities in Kalundborg, Denmark, for the current and future product portfolio within serious chronic diseases. The investment comes as Novo Nordisk…